MONTREAL, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Osisko Metals Incorporated (the "Company" or "Osisko") (TSX: OM; OTCQX: OMZNF; FRANKFURT: 0B51) is pleased to announce initial results from the start of the re-evaluation of the Gaspé Copper Project’s (the "GCP") Porphyry Mountain deposit, discovered in 1994 by mine-site exploration work conducted by Noranda Inc. Osisko’s Deep Porphyry Exploration Project (the "DPEX"), planned for 2026, will include a new deep drill program, re-analysis of historic drill core, and ...

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Osisko Metals Incorporated (the "Company" or "Osisko Metals") (TSX: OM; OTCQX: OMZNF; FRANKFURT: OB51) is pleased to announce the successful closing of its previously-announced "bought-deal" private placement financing, pursuant to which the Company issued an aggregate of 11,812,000 common shares of the Company that will qualify as "flow-through shares" (within the me ...

FDA Approvals & Rejections - Intellia Therapeutics has received FDA approval to resume its MAGNITUDE-2 Phase 3 trial for nexiguran ziclumeran (nex-z) targeting hereditary transthyretin amyloidosis with polyneuropathy, increasing target enrollment from 50 to 60 patients [2][4] - Outset Medical's next-generation Tablo Hemodialysis System has been granted FDA 510(k) clearance, making it the first dialysis device to meet enhanced cybersecurity standards, with shipping expected to begin in Q2 2026 [6][7] - OKYO Pharma has received positive feedback from the FDA for its Phase 2b/3 trial design for Urcosimod, a candidate for neuropathic corneal pain, with plans to start the trial in the first half of 2026 [8][9] - REGENXBIO has faced clinical holds on its RGX-111 and RGX-121 gene therapy programs due to a case of CNS tumor in a child treated with RGX-111, although no similar findings were reported in other patients [10][11] - Almirall has received NMPA approval for Seysara in China for treating moderate-to-severe acne vulgaris, expanding its dermatology portfolio in the region [12][13] Clinical Trials - Breakthroughs - Aprea Therapeutics reported early clinical activity for APR-1051 in endometrial cancer, achieving a 50% reduction in target lesion size in a patient with PPP2R1A-mutated uterine serous carcinoma [19][21] - Fractyl Health's Revita demonstrated positive results in weight maintenance after GLP-1 drug discontinuation, showing a 4.5% weight regain compared to 7.5% in the sham group [22][24] - Ascletis Pharma announced positive Phase 3 results for Denifanstat in moderate-to-severe acne vulgaris, focusing on long-term safety in a trial with 240 patients [25][26] - GRI Bio reported new gene expression data from its Phase 2a study of GRI-0621 in idiopathic pulmonary fibrosis, showing significant improvements in lung injury and fibrosis progression [27][28] - Cardiff Oncology announced encouraging results from its Phase 2 trial of Onvansertib in RAS-mutated metastatic colorectal cancer, with a well-tolerated regimen and plans to advance to a registrational program [31][32] - Genentech's CT-388 Phase 2 trial for obesity showed a significant placebo-adjusted weight loss of 22.5% at 48 weeks, with a high percentage of participants achieving significant weight loss [34][36] - Sarepta Therapeutics reported positive three-year results from its EMBARK study for ELEVIDYS in Duchenne muscular dystrophy, showing significant slowing of disease progression in treated patients [38][41] Deals - YD Bio Limited has signed a letter of intent to acquire Safe Save Medical for approximately $26.87 million, aiming to enhance its capabilities in advanced cellular therapeutics [14][15][17]

Key Takeaways OM shares gain 14.3% after FDA 510(k) clearance for its next-generation Tablo hemodialysis system.OM's redesigned Tablo embeds cybersecurity across hardware, software and cloud.OM plans to ship the new Tablo in Q2 2026, with upgrade eligibility for existing customers.Outset Medical, Inc. (OM) recently announced that its next-generation Tablo hemodialysis system has received 510(k) clearance, marking a key regulatory milestone for the company. The clearance positions Tablo as the first dialysis ...

SAN JOSE, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first-of-its-kind technology to improve clinical outcomes in dialysis with less cost and complexity, today announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) of its next-generation Tablo platform, designed to deliver enterprise-level security, reliability and connectivity for hospitals, health systems and home providers of dialysis. With the clearance, Tablo ...

SAN JOSE, Calif., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the fourth quarter and full-year 2025 after the close of trading on Wednesday, February 11, 2026. On the same day, at 1:30 p.m. Pacific time (4:30 p.m. Eastern time), Leslie Trigg, Chair and Chief Executive Officer, and Renee Gaeta, Chie ...

MONTRÉAL, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Osisko Metals Incorporated (the "Company" or "Osisko Metals") (TSX: OM; OTCQX: OMZNF; FRANKFURT: 0B51) is pleased to announce new drill results from the Gaspé Copper Project, located in the Gaspé Peninsula of Eastern Québec. New analytical results are presented below (see Table 1), including 29 mineralized intercepts from ten new drill holes. Infill intercepts are located inside the 2024 MRE model (see November 14, 2024 news release), and are focused on upgrading ...

Core Insights - Osisko Metals has announced new drill results from the Gaspé Copper Project, highlighting significant mineralization and potential resource expansion [1][2]. Summary by Category Drill Results - The recent drilling program included 35 mineralized intercepts from ten new drill holes, focusing on upgrading inferred mineral resources to measured or indicated categories [2]. - Drill hole 30-1143 (Southern Extension) reported 163.5 metres averaging 0.47% Cu and 3.41 g/t Ag, confirming higher grades in this zone [16]. - Drill hole 30-1142 showed 585.0 metres averaging 0.24% Cu and 245.0 metres averaging 0.55% Cu, indicating significant mineralization depth [15]. - Drill hole 30-1144 reported 748.0 metres averaging 0.27% Cu, extending mineralization to a vertical depth of 895 metres [17]. Mineral Resource Expansion - The current drill program aims to convert the November 2024 Mineral Resource Estimate (MRE) to Measured and Indicated categories and test for deeper and lateral expansions [22]. - The Gaspé Copper Project hosts the largest undeveloped copper resource in eastern North America, with current Indicated Mineral Resources of 824 million tonnes averaging 0.34% CuEq [29]. Geological Context - Mineralization at Gaspé Copper is characterized as porphyry copper/skarn type, with significant occurrences of chalcopyrite, pyrite, and molybdenite [20]. - The drilling strategy involves targeting altered calcareous stratigraphy, intersecting skarn/marble horizons that host the bulk of the disseminated copper mineralization [23]. Future Outlook - The next scheduled MRE update is anticipated in Q1 2026, incorporating new mineralized intersections below the previously defined resource limits [22].

Company Overview - Outset Medical is a California-based med tech company focused on improving dialysis care, aiming to enhance patient outcomes while reducing costs and complexity [2] Market Presence - The company operates in the $2.5 billion acute and post-acute market, with over 1,000 hospitals using its product, Tablo, to deliver approximately 1 million treatments annually [2] - Tablo has been utilized for over 3.5 million treatments in the U.S. [2] - Outset Medical is also establishing a presence in the $8.9 billion home dialysis market, which has been underserved [3]

Outset Medical (NasdaqGS:OM) FY Conference January 14, 2026 07:30 PM ET Company ParticipantsLeslie Trigg - Chair and CEORenee Gaeta - CFODenise Liu - Healthcare Investment Banking AssociateConference Call ParticipantsNone - Analyst 3None - Analyst 1None - Analyst 2Denise LiuHi everyone, my name is Denise Liu. I am an Associate here in Healthcare Investment Banking at JPMorgan. We're excited to be continuing the annual healthcare conference today with Leslie Trigg, Chair and CEO of Outset Medical. We'll have ...